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A b s t r a c t
Introduction: The aim of this study was to assess the relations between 
plasma renin activity (PRA), serum aldosterone concentration (ALDO) and 
selected asymptomatic organ damage (AOD) indices in mild primary arterial 
hypertension (AH). 
Material and methods: We measured PRA, ALDO, and selected AOD indices 
(carotid-femoral pulse wave velocity (cfPWV), central aortic pulse pressure 
(cPP), estimated glomerular filtration rate (eGFR)) in 122 patients with un-
treated AH. 
Results: Patients with high PRA (≥ 0.65 ng/ml/h) were characterized by low-
er plasma sodium and aldosterone to renin ratio (ARR), higher ALDO, but 
a  similar level of AOD indices compared to patients with low PRA. cfPWV 
(p = 0.04) and cPP (p = 0.019) increased with ARR, while eGFR decreased 
with ALDO (p = 0.008). Only eGFR was independently correlated with ALDO. 
In subjects with simultaneously high PRA and ARR values, we found signifi-
cantly higher cfPWV (p = 0.02) and cPP (p = 0.04) and lower eGFR (p = 0.02) 
than in those with high PRA but low ARR values. 
Conclusions: Assessment of the influence of the renin-angiotensin-aldoste-
rone system (RAAS) on AOD should include the relationship between re-
nin and aldosterone. The PRA itself has no predictive value for AOD. More 
advanced arterial stiffness and renal impairment are associated with in-
creased PRA and ARR. The RAAS activity might be useful in AOD prediction 
and hypertension severity assessment.
Key words: essential arterial hypertension, asymptomatic organ damage, 
renin-angiotensin-aldosterone system, plasma renin activity, aldosterone 
Introduction
Overactivity of the renin-angiotensin-aldosterone system (RAAS) is 
characterized by the proliferative, proinflammatory, prothrombotic, and 
profibrotic effects of angiotensin II (Ang II) and aldosterone, and leads to 
increased cardiovascular morbidity and mortality [1, 2]. The main phys-
iological function of aldosterone is to maintain blood pressure (BP) and 
regulate the water-electrolyte balance through renal sodium and water 
reabsorption. An excess of aldosterone causes activation of extrarenal 
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mineralocorticoid receptors, leading to numerous 
cardiovascular complications such as endotheli-
al dysfunction, thrombosis, reduction of vascular 
compliance, baroreceptor function impairment, 
and myocardial and vascular fibrosis. Moreover, 
some authors consider excess of aldosterone as 
an independent cardiovascular risk factor [3]. In 
1991, Dzau and Braunwald proposed the concept 
of a  chain of pathophysiological changes begin-
ning at the cellular level and leading to clinical 
manifestations initiated by up-regulation of the 
RAAS [4]. The results of the double-blind, place-
bo-controlled PATHWAY-2 study revealed that 
mineralocorticoid receptor blockade by spirono-
lactone was the most effective add-on therapy 
for the treatment of resistant hypertension. The 
PATHWAY-2 study demonstrated in a group of 335 
subjects that spironolactone is by far the most 
effective antihypertensive drug to add to triple 
A + C + D therapy (“A” is an angiotensin-converting 
enzyme inhibitor, “C” is a calcium channel block-
er (CCB), and “D” is a thiazide or thiazide-like di-
uretic) for the treatment of resistant hypertension 
when compared to bisoprolol or doxazosin. More-
over, there was a  clear inverse relation between 
the home systolic blood pressure fall with spirono-
lactone and plasma renin, not seen with bisoprolol 
or doxazosin. The results of the PATHWAY-2 study 
give strong and the most contemporary evidence 
that the RAAS-guided therapeutic strategy can be 
useful in clinical practice [5]. Usually, the assess-
ment of the RAAS begins with the measurement 
of plasma renin activity (PRA), which in fact is the 
evaluation of angiotensin I (Ang I) concentration. 
Ang I  is transformed to Ang II, which stimulates 
AT1 receptors and promotes inflammation, free 
radical generation, endothelial dysfunction, vaso-
constriction, plaque generation, and remodeling 
of the deeper layers of the vessel wall through 
processes such as smooth muscle cell hyperplasia 
and stromal fibrosis [1, 6]. The early consequenc-
es of these processes are myocardial remodeling, 
hypertrophy and fibrosis, renal damage, ultimately 
leading to late clinical outcomes such as ischemic 
heart disease, heart failure and chronic kidney 
disease [7].
The cardiovascular and renal asymptomatic or-
gan damage (AOD) indices associated with arteri-
al hypertension were listed by the ESH/ESC 2013 
Guidelines [8], and included left ventricular mass 
index (LVMI), carotid intima-media thickness 
(IMT), aortic pulse wave velocity (PWV), and esti-
mated glomerular filtration rate (eGFR). Theoreti-
cally, the values of these indices should be higher 
in patients with increased RAAS activity. However, 
there are limited and sometimes contradictory 
data supporting this hypothesis [9–11]. Accord-
ing to the ESH/ESC Guidelines, besides lowering 
BP, the main aim of antihypertensive therapy is to 
halt the progression of AOD [8]. The extent of AOD 
cannot be explained by the hemodynamic effect 
of higher blood pressure alone. A hypothesis that 
a connection exists between higher RAAS activity 
and the progression of AOD has been proposed, 
and we believe that confirming such a  relation-
ship would be clinically useful. 
Elevated renin activity is responsible for ap-
proximately 70% of essential hypertension cas-
es. This form of hypertension is described as 
renin-mediated hypertension (R-hypertension). 
Angiotensin-converting enzyme inhibitors, an-
giotensin receptor blockers, and β-blockers are 
particularly effective in this kind of hypertension. 
If the hypothesis outlined above is confirmed, it 
will become possible to administer proper, target-
ed antihypertensive therapy to slow the progres-
sion of AOD if a patient’s PRA level is known [12].
With the above in mind, the aim of this study 
was to assess the associations of PRA and ALDO 
with several AOD indices in patients with essen-
tial arterial hypertension.
Material and methods 
This study was scheduled as a prospective trial. 
The study group comprised consecutive, non-se-
lected patients (men and women in equal num-
ber), newly referred to our outpatient clinic within 
1.07.2013–31.12.2013. Patients aged 30–75 years 
with essential arterial hypertension stage-1 ac-
cording to the 2013 ESH/ESC Guidelines [8] (i.e. 
arterial blood pressure values ≥ 140/90 mm Hg 
and < 160/100 mm Hg) were enrolled. Patients 
with previously diagnosed and treated hyperten-
sion were included in the study after a minimum 
6-week drug washout period. In order to exclude 
secondary hypertension in all patients abdominal 
ultrasound examination with renal Doppler flow 
assessment was performed. Subjects with sus-
pected renal artery stenosis were excluded. Other 
exclusion criteria were: history of coronary artery 
disease, i.e. myocardial infarction, angina pecto-
ris, a history of coronary revascularization, as well 
as cardiac valvular disease, atrial fibrillation, prior 
stroke or transient ischemic attack, antiplatelet, 
anticoagulant, or lipid-lowering therapy, acute 
or chronic inflammation, cancer, chronic kidney 
disease (i.e. eGFR below 60 ml/min/1.73 m2) or 
liver failure. Insulin-treated diabetic patients and 
pregnant women were also excluded. Accounting 
for aforementioned exclusion criteria, 229 from 
360 initially screened subjects were excluded. 
Although the study group included only patients 
with mild essential arterial hypertension without 
typical indications to perform screening for pri-
mary aldosteronism according to the Endocrine 
Society Guidelines [13], we decided to exclude 
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patients with an aldosterone-to-renin ratio (ARR) 
> 100 ng/dl/ng/ml/h and aldosterone concentra-
tion > 30 ng/dl. According to the latest exclusion 
criteria 9 patient were excluded. In this group 
1 case of primary hyperaldosteronism (adenoma), 
1 case of cancer with ectopic corticoid secretion 
and 1 case of unilateral hydronephrosis were con-
firmed. 
In the hypertensive group, 89 (73%) patients were 
antihypertensive therapy naïve, while 33 (27%) 
patients had been previously treated with one or 
a  combination of two antihypertensive drugs at 
low doses. In this group, 6 patients had previous-
ly received slow-release indapamide (1.5 mg) as 
monotherapy during 1–4 months before the study, 
five lisinopril (5–10) mg twice daily as monother-
apy for a  period of 2–3 months, five perindopril 
(5 mg) once daily for a  period of 1–3 months, 
three valsartan (80 mg) once daily for a  period 
of 1–3 months, three verapamil (120 mg/day) 
for 1–3 months, three carvedilol (6.125–12.5 mg) 
twice daily for a period of 1–4 months, two me-
toprolol succinate 50 mg/day (one for a  peri-
od of 2 months and one for 3 months), and five 
combination therapy consisting of indapamide 
(0.625 mg) plus perindopril (2.5 mg) once daily 
for 2–3 months. The above-mentioned treatments 
were withdrawn at least 6 weeks before enrollment.
Study procedures
All subjects signed an informed consent form 
for inclusion in this study. The Jagiellonian Univer-
sity Ethics Committee approved the protocol of 
the study (decision number: KBET/7/B/2007). The 
following assessments were performed:
1. Office BP measurements were performed un-
der standard conditions, twice at an interval 
of one minute on the non-dominant arm after 
5 min rest in the sitting position. All procedures 
were performed in accordance with the recom-
mendations of the European Society of Hyper-
tension [13] using the Omron M5-I oscillome-
tric device (Omron Healthcare Co., Japan). The 
average of the obtained values was entered 
into the final analysis.
2. Twenty-four-hour ambulatory BP monitoring 
was performed using a  SpaceLabs 90207 re-
corder (SpaceLabs Inc, Richmond, Washington, 
USA) according to the ESH working group’s 
practice guidelines [14], with automatic mea-
surements taken at 15-min intervals during 
daily activity and 20-min intervals during night-
time hours. 
3. Carotid-femoral PWV was measured with 
a  SphygmoCor (AtCor Medical, Sydney, Aus-
tralia) device. Aortic central BP was calculated 
based on transfer function from tonometric re-
cording of pulse wave in the radial artery and 
BP measured in the brachial artery. The cfPWV 
measurements were made in accordance with 
the recommendations of the ‘Expert consensus 
document on arterial stiffness: methodologi-
cal issues and clinical applications’ published 
in 2006 [15], and the ‘Expert consensus doc-
ument on the measurement of aortic stiffness 
in daily practice using carotid-femoral pulse 
wave velocity’ published in 2012 [16]. Data 
were collected by a  single trained examiner 
and the mean of at least 2 PWV and 2 pulse 
wave analysis (central blood pressure) mea-
surements was taken for each subject. In ad-
dition, measurements were accepted as valid 
only when the difference did not exceed 10%. 
However, to allow more effective comparisons 
of our results with those previously published, 
we did not multiply the distance measured on 
the body surface between the carotid and fem-
oral arteries by 0.8 as recommended by the lat-
ter document [16].
4. Echocardiographic examination was performed 
with a Vivid 7 VingMed (GE-Healthcare Chica-
go, IL, USA) device and 1.7–3.4 MHz harmonic 
transducer with the patient in the partial left 
decubitus position in typical echocardiograph-
ic views. Left-ventricular dimensions, inter-
ventricular septum, and posterior wall thick-
ness were measured using M-mode imaging. 
Left-ventricular mass (LVM) was calculated by 
the Devereux formula [17]. LVM index (LVMI) 
was calculated using this LVM result and body 
surface area. 
5. The degree of vascular remodeling was eval-
uated by ultrasonography-derived IMT mea-
surements in the common carotid artery. Mea-
surements were performed manually in the 
two-dimensional long-axis view using a  linear 
10-MHz probe (Vivid 7, VingMed, GE-Health-
care Chicago, IL, USA). The IMT was measured 
within the near and far walls of both common 
carotid arteries, 2 cm proximally to the bifurca-
tion. Three measurements were performed at 
each arterial site. We evaluated the mean value 
of all measurements from each site. The meth-
odology was in agreement with the Mannheim 
consensus [18]. 
6. All echocardiographic and carotid artery ultra-
sound examinations were performed by two 
independent examiners. To assess intraobserv-
er and interobserver variabilities in LVMI and 
IMT measurements, 15 patients were randomly 
selected and measurements were taken by the 
main observer on two separate occasions and 
another independent observer. We computed 
the coefficient of variation as the ratio of the 
mean difference between repeat measure-
ments to the standard deviation of the paired 
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differences multiplied by 100. In the case of 
LVMI intraobserver and interobserver variabil-
ities were 4% and 6%, respectively. In the case 
of IMT intraobserver and interobserver variabil-
ities were 3% and 7%.
7. Directly after the assessment of instrumental 
AOD indices venous blood was collected in the 
morning hours after a 12 h fast with patients in 
the sitting position. Blood was collected in sili-
cone-treated glass tubes containing EDTA, and 
plasma was immediately separated and frozen 
at –75°C until required. Serum aldosterone con-
centration was determined by radioimmunoas-
say using the ALDO-RIACT kit (Cisbio Bioassays, 
Codolet, France), with a  limit of detection of 
7 pg/ml and a  coefficient of variation < 7.5%. 
Plasma renin activity was determined from the 
same sample by radioimmunoassay using the 
Ang I  RIA KIT (Beckman Coulter, Immunotech, 
Prague, Czech Republic) with a sensitivity of 0.07 
ng/ml and coefficient of variation < 6.0%. Serum 
creatinine concentration was measured using 
the Jaffe reaction method. Serum concentrations 
of sodium and potassium were measured using 
the indirect ion selective electrode method. Rou-
tine biochemical assessments were performed 
using a Hitachi 917/Modular P automatic analyz-
er (Roche Diagnostics Ltd). Estimated glomerular 
filtration rate (eGFR) was calculated using the 
Modification of Diet in Renal Disease (MDRD) 
formula [19].
Statistical analysis
We used SAS, version 9.1 (SAS Institute Inc, Cary, 
NC) for data management and statistical analysis. 
Variables were analyzed for normal distribution us-
ing the Shapiro-Wilk test and non-parametric tests 
were used for non-normally distributed variables. 
For exploratory analyses, we assessed the char-
acteristics of participants by groups according to 
the distribution of PRA. To compare proportions 
and means we applied the c2 test and Student’s 
t-test (or one-way analysis of variance), respec-
tively. Our statistical methods also included linear 
regression and multivariate-adjusted linear regres-
sion with AOD indices as the dependent variables. 
The possible covariates accounted for in analyses 
were searched using stepwise regressions with the 
F-value for independent variables to enter and stay 
in the model set at 0.10. A value of p < 0.05 was 
considered significant in all statistical analyses.
Results
Characteristics of the study group
The study group consisted of 122 patients with 
essential uncomplicated stage 1 arterial hyperten-
sion (61 men and 61 women). Based on the ob-
tained PRA results, patients were divided into two 
subgroups, ‘low-renin’ and ‘high-renin’, according 
to the Laragh and Alderman criteria (low-renin: 
PRA < 0.65 ng/ml/h, high-renin: PRA ≥ 0.65 ng/
ml/h) [12]. Basic clinical and biochemical charac-
teristics, BP values, and indices of organ damage 
in the study group and comparisons between low- 
and high-renin groups are presented in Table I.
In the high-renin group, lower plasma sodium 
concentrations, higher ALDO, heart rate and 5-fold 
lower ARR were observed compared to the low-re-
nin group. No between-group differences were ob-
served with respect to office BP and 24-h ambula-
tory BP values, as well as AOD indices.
Regression analyses of AOD and RAAS 
indices
Linear regression analyses for AOD indices 
(cfPWV, cPP, IMT, LVMI, and eGFR) and RAAS indi-
ces (PRA, ALDO, and ARR) were performed to as-
sess the association of AOD indices with the pa-
rameters of RAAS.
A significant positive association was found be-
tween cPP and ARR (β = 0.117, p = 0.019) as well 
as between cfPWV and ARR (β = 0.112, p = 0.04). 
In linear regression analysis, eGFR was significant-
ly negatively associated with ALDO (β = –0.663, 
p = 0.008). In multivariate regression analysis in-
cluding age, sex and BMI, only the negative asso-
ciation between eGFR and ALDO remained statis-
tically significant (Table II).
Comparison of three groups defined based 
on PRA and ARR values
Because PRA alone did not determine differ-
ences in AOD for further analyses, we divided the 
study group into four subgroups depending on 
PRA level and ARR (Figure 1). PRA below or over 
0.65 ng/ml/h and the median value of ARR in our 
study (18.42 ng/dl/ng/ml/h) were used to create 
four subgroups as follows:
–  group 1: PRA < 0.65 ng/ml/h and ARR ≥ 18.42 ng/ 
dl/ng/ml/h (number of subjects N = 51),
–  group 2: PRA ≥ 0.65 ng/ml/h and ARR < 18.42 ng/ 
dl/ng/ml/h (N = 58),
–  group 3: PRA ≥ 0.65 ng/ml/h and ARR ≥ 18.42 ng/ 
dl/ng/ml/h (N = 12),
–  group 4: PRA < 0.65 ng/ml/h and ARR < 18.42 ng/ 
dl/ng/ml/h (N = 1).
Group 4 was excluded from further analyses 
because only 1 patient was included. The three re-
maining groups were compared using analysis of 
variance (Table III), which revealed significant be-
tween-group differences in cfPWV, cPP and eGFR. 
Subjects in group 3 had significantly higher cfPWV 
and cPP and significantly lower eGFR values com-
pared to those in group 2 (Figure 2). These differ-
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ences remained significant for pulse wave velocity 
and glomerular filtration rate after adjustment for 
age.
Discussion
In this study, we assessed the relationship 
between RAAS indices and a  wide spectrum of 
asymptomatic organ damage indices in patients 
with mild essential hypertension. Most of the pre-
vious studies assessed only a single AOD index or 
several selected AOD indices. Hypothetically, high-
er RAAS activity should promote and accelerate 
the development of AOD. However, the available 
data do not consistently support this hypothesis. 
For example, Schunkert et al. found that in both 
men and women, serum aldosterone concentra-
tion was strongly related to septal and posterior 
wall thickness. Furthermore, in women, ALDO 
was positively and independently associated with 
LVMI. However, in the same study, no significant 
associations with LVMI were observed for angio-
tensinogen, renin, or pro-renin [9].
Table I. Clinical characteristics of study group
Clinical characteristics All participants High renin
PRA ≥ 0.65 ng/ml/h
Low renin PRA  
< 0.65 ng/ml/h
P-value#
N 122 72 50
Age [years] (SD) 53.3 (12.9) 52.2 (13.3) 55.4 (10.9) 0.15
Sex, male (%) 61 (50) 37 (51) 24 (48) 0.90
BMI [kg/m2] (SD) 27.4 (4.5) 27.2 (4.4) 27.4 (4.9) 0.88
Diabetes mellitus type 2 (%) 7 (5.7) 5 (6.9) 2 (4.0) 0.47
Smokers (%) 26 (21.3) 15 (20.8) 11 (22.0) 0.91
SBP [mm Hg]* 150.5 (18.9) 148.1 (18.9) 154.2 (18.5) 0.10
DBP [mm Hg]* 92.3 (10.6) 91.9 (11.5) 92.9 (9.2) 0.62
HR [beats/min]* 73.2 (9.1) 74.3 (10.2) 71.3 (9.3) 0.13
Sodium [mmol/l] 138.6 (2.5) 137.9 (2.4) 139.5 (2.3) 0.001
Potassium [mmol/l] 4.2 (0.2) 4.20 (0.3) 4.16 (0.31) 0.44
PRA [ng/ml/h] 1.3 (1.9) 2.08 (2.34) 0.31 (0.14) < 0.001
ALDO [ng/dl] 14.8 (7.1) 15.9 (7.9) 13.2 (5.6) 0.049
ARR [ng/dl/ng/ml/h] 30.0 (32.3) 11.4 (6.8) 54.4 (36.2) < 0.001
ABPM:
SBP 24 h [mm Hg] 130.8 (9.1) 131.4 (9.4) 129.9 (8.9) 0.41
DBP 24 h [mm Hg] 80.4 (7.6) 81.7 (7.7) 79.2 (7.3) 0.13
HR 24 h [beats/min] 75.6 (9.1) 77.7 (8.8) 72.6 (8.8) 0.017
SBP day [mm Hg] 135.4 (10.0) 136.2 (10.2) 134.3 (9.7) 0.54
DBP day [mm Hg] 84.7 (8.1) 86.1 (8.1) 82.8 (8.2) 0.07
HR day [beats/min] 79.8 (9.9) 82.3 (9.6) 76.4 (9.6) 0.01
SBP night [mm Hg] 121.1 (9.6) 121.4 (9.8) 120.8 (9.5) 0.91
DBP night [mm Hg] 72.4 (8.1) 72.8 (8.9) 71.8 (6.9) 0.55
HR night [beats/min] 67.0 (8.5) 68.6 (8.1) 64.8 (8.5) 0.06
Target organ characteristics:
cfPWV [m/s] 8.27 (1.8) 8.19 (1.7) 8.4 (1.9) 0.59
cPP [mm Hg] 45.8 (16.7) 44.3 (15.5) 47.9 (15.3) 0.22
Creatinine [µmol/l] 66.7 (12.6) 66.6 (12.3) 66.4 (14.1) 0.94
eGFR [ml/min/1.73 m2] 97.4 (18.7) 97.8 (18.4) 96.9 (19.5) 0.68
LVMI [g/m2] 129.3 (33.6) 131.0 (34.6) 127.2 (37.4) 0.70
IMT [mm] 0.64 (0.15) 0.64 (0.15) 0.63 (0.16) 0.47
Data are expressed as mean (SD) or number of persons (percentage, %). *Mean of two measurements, #p-value for differences between 
low and high renin groups. PRA – plasma renin activity, BMI – body mass index, SBP – systolic blood pressure, DBP – diastolic blood 
pressure, HR – heart rate, ALDO – aldosterone plasma concentration, ARR – aldosterone to renin ratio, ABPM – ambulatory blood pressure 
monitoring, cfPWV – carotid-femoral pulse wave velocity, cPP – central pulse pressure, eGFR – estimated glomerular filtration rate, LVMI 
– left ventricular mass index, IMT – intima-media thickness in common carotid artery (average value from measurements of near and far 
walls on both sides).
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In a cohort of patients with arterial hyperten-
sion, who had never been treated, Catena et al. 
demonstrated that higher ALDO but not higher 
PRA characterized patients with left ventricle hy-
pertrophy [20]. Edelmann et al. found in a group 
of 1575 patients with preserved ejection fraction 
a significant correlation between serum aldoste-
rone concentration and LVM in women but not 
in men [21]. In a  group of children with arterial 
hypertension, Loureiro et al. demonstrated an as-
sociation between carotid IMT and aldosterone as 
well as ARR. Such association was not confirmed 
for PRA. The multivariate regression analysis re-
ported by Laureiro et al. revealed that ARR was 
the only variable that explains changes in carotid 
IMT [10]. Lee and Lai showed that PRA and ARR 
but not aldosterone are independently associated 
with the presence of carotid plaques in patients 
with coronary artery disease [22].
In the present study, we did not detect a signif-
icant relationship between LVMI or IMT and RAAS 
indices. The most likely explanation for this was 
the small size of the study group. Previous stud-
ies revealing (for example) significant changes of 
LVMI or IMT under the influence of antihyperten-
sive treatment were large population-based stud-
ies or meta-analyses of many studies [23, 24].
In the present study, arterial stiffness indices: 
cfPWV and cPP were significantly associated with 
ARR. We consider this result to be important in the 
light of previously published results. Kisaka et al. 
demonstrated over a long-term observation peri-
od that high ARR is an independent risk factor for 
cardiovascular events in patients with essential 
hypertension [25]. Moreover, Newton-Cheh et al. 
found that increased ARR was a  hereditary fac-
tor of arterial hypertension. In non-hypertensive 
participants, the authors observed that a gradu-
al increase in baseline ARR was associated with 
significantly increased risk for the progression of 
high BP and incident hypertension, and that renin 
and aldosterone were more predictive of BP out-
comes together than either hormone alone [26].
Table II. Determinants of studied asymptomatic organ damage parameters in the whole group
Parameter cfPWV cPP eGFR
R2 0.25 0.15 0.22 
Age [years]
β ± SE 0.48 ±0.088# 0.37 ±0.095# –0.38 ±0.090#
Gender (0 men 1 women)  
β ± SE –0.11 ±0.089 0.08 ±0.094 –0.11 ±0.089 
BMI
β ± SE 0.20 ±0.087# 0.044 ±0.093 0.10 ±0.088 
PRA 
β ± SE –0.05 ±0.094 –0.04 ±0.097 0.12 ±0.093 
ALDO 
β ± SE 0.11 ±0.091 0.13 ±0.097 –0.27 ±0.095# 
Significance of the partial regression coefficient: NS p ≥ 0.10; *p < 0.10; #p < 0.05. cfPWV – carotid-femoral pulse wave velocity, cPP – 
central pulse pressure, eGFR – estimated glomerular filtration rate, BMI – body mass index, PRA – plasma renin activity, ALDO – aldosterone 
plasma concentration.
Figure 1. Subgroups created from study group ac-
cording to PRA and median of ARR values. Group 1:  
PRA < 0.65 ng/ml/h and ARR ≥ 18.42 ng/dl/ng/
ml/h (N = 51), group 2: PRA ≥ 0.65 ng/ml/h and 
ARR < 18.42 ng/dl/ng/ml/h (N = 58), group 3:  
PRA ≥ 0.65 ng/ml/h and ARR ≥ 18.42 ng/dl/ng/
ml/h (N = 12), group 4: PRA < 0.65 ng/ml/h and 
ARR < 18.42 ng/dl/ng/ml/h (N = 1)
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The highest values of cfPWV and cPP in the 
present study were observed in patients with 
high PRA and ARR, i.e. with relatively high ALDO. 
Tzamou et al. (in a study methodologically similar 
to the present one) found that higher values of 
arterial stiffness indices (including cfPWV) were 
present in patients with increased ALDO and high 
aldosterone urine secretion levels. However, the 
correlations between arterial stiffness and RAAS 
indices obtained in that study were rather weak 
[11]. Tomaschitz et al. demonstrated in a  large 
cohort of patients undergoing coronary angiogra-
Table III. Comparison of three groups defined based on PRA and ARR values. Group 1: PRA < 0.65 ng/ml/h and ARR 
≥ 18.42 ng/dl/ng/ml/h (N = 51); group 2: PRA ≥ 0.65 ng/ml/h and ARR < 18.42 ng/dl/ng/ml/h (N = 58); group 3: 
PRA ≥ 0.65 ng/ml/h and ARR ≥ 18.42 ng/dl/ng/ml/h (N = 12)
Clinical characteristics Group 1 Group 2 Group 3 PANOVA
N 51 58 12
Age [years] (SD) 55.4 (11.3) 51.9 (13.2) 57.6 (13.7) 0.26
Sex, male (%) 23 (45) 31 (53) 6 (50) 0.64
BMI [kg/m2] (SD) 27.2 (4.7) 27.2 (4.7) 26.0 (2.9) 0.80
Diabetes mellitus type 2 (%) 2 (3.9) 4 (6.9) 1 (8.3) 0.57
Smokers (%) 11 (21.6) 12 (20.7) 2 (16.7) 0.81
SBP [mm Hg]* 155.0 (18.5) 147.1 (20.6) 153.2 (15.5) 0.16
DBP [mm Hg]* 92.8 (9.4) 90.7 (12.3) 94.2 (7.7) 0.60
HR [beats/min]* 69.3 (8.6) 75.7 (10.1) 66.6 (12.2) 0.017#,^
Sodium [mmol/l] 139.5 (2.3) 138.1 (2.5) 137.0 (1.4) 0.002#,$
Potassium [mmol/l] 4.16 (0.31) 4.18 (0.24) 4.37 (0.28) 0.15
PRA [ng/ml/h] 0.32 (0.15) 2.26 (2.42) 1.07 (0.47) < 0.001#,$
ALDO [ng/dl] 13.4 (5.4) 14.9 (6.5) 20.8 (7.7) < 0.001$,^
ARR [ng/dl/ng/ml/h] 39.0 (27.1) 11.2 (6.4) 22.8 (9.7) < 0.001#
ABPM:
SBP 24 h [mm Hg] 130.2 (9.3) 31.3 (9.5) 132.7 (9.5) 0.84
DBP 24 h [mm Hg] 78.8 (7.4) 81.1 (7.3) 84.0 (9.6) 0.28
HR 24 h [beats/min] 71.6 (8.1) 76.9 (9.3) 72.0 (10.6) 0.002#
SBP day [mm Hg] 128.9 (12.0) 128.4 (12.4) 132.6 (12.1) 0.67
DBP day [mm Hg] 80.0 (8.2) 80.6 (9.8) 85.7 (9.3) 0.26
HR day [beats/min] 75.5 (9.4) 81.4 (10.2) 74.9 (11.2) 0.01#
SBP night [mm Hg] 115.3 (11.7) 112.2 (11.4) 120.4 (8.7) 0.11
DBP night [mm Hg] 68.2 (7.8) 66.4 (8.8) 74.0 (10.1) 0.06
HR night [beats/min] 64.2 (8.2) 67.2 (8.1) 65.1 (9.8) 0.20
Target organ characteristics:
cfPWV [m/s] 8.2 (1.85) 8.0 (1.50) 10.0 (2.3) 0.02^
cPP [mm Hg] 48.3 (15.5) 42.5 (16.9) 56.0 (21.7) 0.04^
Creatinine [µmol/l] 67.2 (12.8) 65.7 (13.0) 72.4 (9.0) 0.33
eGFR [ml/min/1.73 m2] 95.2 (19.7) 100.0 (18.4) 81.1 (12.2) 0.02^
LVMI [g/m2] 127.2 (34.7) 131.0 (34.6) 130.5 (22.3) 0.85
IMT [mm] 0.65 (0.15) 0.60 (0.15) 0.69 (0.16) 0.61
Data are expressed as mean (SD) or number of persons (percentage, %). *Mean of two measurements, #p < 0.05 for differences between 
G1 and G2; $p < 0.05 for differences between G1 and G3; ^p < 0.05 for differences between G2 and G3. PRA – plasma renin activity, 
ARR – aldosterone to renin ratio, BMI – body mass index, SBP – systolic blood pressure, DBP – diastolic blood pressure, HR – heart rate, 
ALDO – aldosterone plasma concentration, ABPM – ambulatory blood pressure monitoring, cfPWV – carotid-femoral pulse wave velocity, 
cPP – central pulse pressure, eGFR – estimated glomerular filtration rate, LVMI – left ventricular mass index, IMT – intima-media thickness 
in common carotid artery (average value from measurements of near and far walls on both sides).
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phy (N = 3056) that a positive correlation exists 
between ARR and peripheral and central BP [27]. 
This finding is in full accordance with our results 
concerning cPP. Meanwhile, the results obtained 
by Mahmud and Feely are only partially congruent 
with our findings [28]. These authors demonstrat-
ed a significant, positive correlation between ARR 
and aortic pulse pressure, but not aortic PWV.
In summary, the stiffness of the large arteries 
seems to depend on RAAS activity, and especial-
ly on ALDO. Arterial stiffening is probably one of 
the most important long-term harmful effects of 
aldosterone in the cardiovascular system. In a pre-
vious study comparing the influences of different 
antihypertensive drugs on cfPWV, decreased cf-
PWV was accompanied by decreased ALDO. The 
latter relationship reached statistical significance 
in the ACE-inhibitor (quinapril)-treated group [29].
The ESH/ESC Guidelines state that eGFR in the 
range 30–60 ml/min/1.73 m2 is one of the mark-
ers of AOD in patients with arterial hypertension 
[8]. However, even less pronounced renal func-
tion impairment can indicate higher cardiovascu-
lar risk. In the VALIANT trial (Valsartan in Acute 
Myocardial Infarction Trial) the risk of death and 
composite end point – death from cardiovascular 
causes, congestive heart failure, recurrent myocar-
dial infarction, resuscitation after cardiac arrest, 
and stroke – increased with decreasing GFR in 
a 2-year follow-up of 14.5 thousand patients with 
myocardial infarction complicated by heart failure 
or left ventricular dysfunction. It is worth empha-
sizing that this relationship occurred from a rela-
tively high value of GFR – i.e. 81 ml/min/1.73 m2 
– below which any decline in GFR of 10 units was 
associated with an increase in the risk coefficient 
for death and cardiovascular complications of 
1.10 [30]. 
In the Kaiser Permanente Southern Califor-
nia study, higher levels of PRA were found to be 

































































































 Group 1 Group 2 Group 3  Group 1 Group 2 Group 3  Group 1 Group 2 Group 3
p = 0.02 p = 0.04 p = 0.02
Figure 2. ANOVA for groups distinguished according to PRA and ARR values. Group 1: PRA < 0.65 ng/ml/h and ARR 
≥ 18. 4 ng/dl/ng/ml/h, group 2: PRA ≥ 0.65 ng/ml/h and ARR < 18.4 ng/dl/ng/ml/h, group 3: PRA ≥ 0.65 ng/ml/h 
and ARR ≥ 18.4 ng/dl/ng/ml/h. Values presented as means ± standard error.
PRA – plasma renin activity, ARR – aldosterone to renin ratio, pulse wave velocity – carotid-femoral pulse wave velocity measured 
using Sphygmocor device, central pulse pressure
 
– central aortic pulse pressure measured using Sphygmocor device, glomerular 
filtration rate – estimated glomerular filtration rate using MDRD formula [18].
A B C
disease (CKD), while increased ARR was inversely 
correlated with the frequency of CKD [7]. Contra-
dictory results were obtained in a  Japanese pop-
ulation in the Ohasama Study, where lower PRA 
and higher ARR were associated with the devel-
opment of CKD in the general population, sug-
gesting that they are independent predictors of 
CKD [31]. These discrepant results probably arose 
from ethnic differences and different eating hab-
its, particularly those concerning salt intake. In our 
study, patients with high renin levels had simulta-
neously high ARR, and in consequence relatively 
high serum aldosterone concentration. This group 
of patients also had the lowest eGFR values. We 
demonstrated, using multiple regression, that 
aldosterone concentration was in our group of 
patients significantly and independently associ-
ated with the eGFR value. Furthermore, the most 
severe configuration of RAAS indices in terms of 
renal dysfunction was simultaneously increased 
renin and ARR. These results indicate that eGFR 
should be calculated with the MDRD formula in 
all patients with essential arterial hypertension 
and an exact value, rather than a rough estimate 
(> 60 ml/min/1.73 m2), should be determined.
Despite the fact that increased RAAS activity 
worsens the prognosis for survival and cardiovas-
cular events as indirectly evidenced in large clinical 
trials with different drugs reducing RAAS cascade 
components (in heart failure, ischemic heart disease 
and arterial hypertension) [8, 32–35], many other 
studies (cited by us previously) are still focused on 
the relationships between RAAS activity and AOD 
indices. In the early stages of arterial hypertension 
this is due to the need to identify the subjects in 
whom treatment with RAAS blocking agents can 
bring the greatest clinical benefits. Another reason 
to search for the RAAS phenotype associated with 
more advanced AOD is the greater availability and 
lower cost of PRA, aldosterone and ARR determi-
nation compared to the assessment of broad spec-
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trum AOD indices using echocardiographic, carotid 
ultrasound and arterial stiffness examination. If 
such a phenotype might be predefined (according 
to the results of our study it is the configuration of 
simultaneously high PRA and high ARR), this might 
limit and specify the indication for AOD assessment.
The most important limitation of this study was 
the relatively small sample size. The consequences 
of the small sample size might be: low represen-
tativeness for the general population, overestima-
tion of the obtained effect, high risk of unknown 
confounding factor presence, e.g. the duration of 
undiagnosed hypertension, random error and low 
reproducibility of results. Therefore, the obtained 
results need to be confirmed in a larger group of 
patients. In addition, previous antihypertensive 
treatment in about 30% of patients could have in-
fluenced our investigation of AOD indices. Another 
limitation of our study is the lack of data regard-
ing sodium intake and urinary sodium excretion, 
which potentially may influence PRA and aldoste-
rone levels and subsequently affect BP and target 
organ damage to a varying degree depending on 
salt sensitivity [36]. However, valuable and repro-
ducible assessment of sodium intake in individual 
subjects, even assessed by 24-hour urine collec-
tion, considered as a gold standard, is hardly pos-
sible [36]. That is why we did not decide to include 
this parameter in our study. Moreover prospective 
cohort studies have reported that the association 
between sodium consumption and cardiovascular 
disease or mortality is U-shaped, with increased 
risk at both high and low sodium intake [37].
In conclusion, taking into consideration dis-
crepancies concerning the relationships among 
PRA, aldosterone, ARR, and kidney disease dis-
cussed previously, the interdependences of these 
indices are likely very important and should be 
routinely assessed in relevant patients. Lee and 
Lai made a similar statement concerning the re-
lationship between carotid atherosclerosis and 
RAAS indices [22], and we believe that in the light 
of the results of the present study, this statement 
should be extended to kidney damage and arterial 
stiffness indices. The simultaneous assessment of 
PRA, ALDO, and ARR should be performed to allow 
better prognosis of kidney damage and prediction 
of the development of arterial stiffness.
Acknowledgments
Tomasz Pizoń and Marek Rajzer contributed 
equally to this work.
This work was supported by the Polish Minis-
try of Science & Higher Education under Grant no. 
NN402367333.
Conflict of interest
The authors declare no conflict of interest.
R e f e r e n c e s
1. Marney AM, Brown NJ. Aldosterone and end-organ 
damage. Clin Sci 2007; 113: 267-78.
2. Mlak R, Homa-Mlak I, Powrózek T, et al. Impact of I/D 
polymorphism of ACE gene on risk of development and 
course of chronic obstructive pulmonary disease. Arch 
Med Sci 2016; 12: 279-87.
3. Funder JW, Reincke M. Aldosterone: a  cardio-
vascular risk factor? Biochim Biophys Acta 2010; 1802: 
1188-92.
4. Dzau V, Braunwald E. Resolved and unresolved 
issues in the prevention and treatment of coronary 
artery disease: a  workshop consensus statement. Am 
Heart J 1991; 121: 1244-63.
5. Williams B, MacDonald TM, Morant S, et al. Spi-
ronolactone versus placebo, bisoprolol, and doxazosin 
to determine the optimal treatment for drug-resistant 
hypertension (PATHWAY-2): a randomized, double-blind, 
crossover trial. Lancet 2015; 386: 2059-68.
6. Ferrario CM, Strawn WB. Role of the renin-angiotensin- 
aldosterone system and proinflammatory mediators in 
cardiovascular disease. Am J Cardiol 2006; 98: 121-8.
7. Sim JJ, Shi J, Calara F, Rasgon S, Jacobsen S, Kalantar- 
Zadeh K. Association of plasma renin activity and aldo-
sterone-renin ratio with prevalence of chronic kidney 
disease: the Kaiser Permanente Southern California co-
hort. J Hypertens 2011; 29: 2226-35.
8. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ 
ESC Guidelines for the management of arterial hyper-
tension. J Hypertens 2013; 31: 1281-357.
9. Schunkert H, Hense HW, Muscholl M, et al. As-
sociations between circulating components of the re-
nin-angiotensin-aldosterone system and left ventricular 
mass. Heart 1997; 77: 24-31.
10. Loureiro C, Campino C, Martinez-Aguayo A, et al. Pos-
itive association between aldosterone-renin ratio and 
carotid intima-media thickness in hypertensive chil-
dren. Clin Endocrinol 2013; 78: 352-7.
11. Tzamou V, Kyvelou SM, Karpanou E, Petras D, Vyssou- 
lis G. Aldosterone levels, aortic stiffness, and wave re-
flection in essential hypertensive patients. Am J Hyper-
tens 2015; 28: 852-7.
12. Laragh JH. Laragh’s Lesson in Renin System Pathophysi-
ology for Treating Hypertension and its Fatal Cardiovas-
cular Consequences. Elsevier, New York 2002.
13. Funder JW, Carey RM, Mantero F, et al. The management 
of primary aldosteronism: case detection, diagnosis, 
and treatment: an Endocrine Society Clinical Practice 
Guideline. J Clin Endocrinol Metab 2016; 101: 1889-916.
14. O’Brien E, Parati G, Stergiou G, et al. European Society of 
Hypertension position paper on ambulatory blood pres-
sure monitoring. J Hypertens 2013; 31: 1731-68.
15. Laurent S, Cockcroft J, Van Bortel L, et al. Expert con-
sensus document on arterial stiffness: methodological 
issues and clinical applications. Eur Heart J 2006; 27: 
2588-605.
16. Van Bortel LM, Laurent S, Boutouyrie P, et al. Expert con-
sensus document on the measurement of aortic stiff-
ness in daily practice using carotid-femoral pulse wave 
velocity. J Hypertens 2012; 30: 445-8.
17. Devereux RB, Alonso DR, Lutas EM, et al. Echocardio-
graphic assessment of left ventricular hypertrophy: 
comparison to necropsy findings. Am J Cardiol 1986; 57: 
450-8.
18. Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim 
carotid intima-media thickness and plaque consensus 
(2004-2006-2011). An update on behalf of the advisory 
Tomasz Pizoń, Marek Rajzer, Wiktoria Wojciechowska, Tomasz Drożdż, Dorota Drożdż, Marta Rojek, Krystian Gruszka, Danuta Czarnecka
18 Arch Med Sci 1, December / 2020
board of the 3rd, 4th and 5th Watching the Risk Symposia 
at the 13th, 15th and 20th European Stroke Conferences, 
Mannheim Germany, 2004, Brussels, Belgium, 2006, 
and Hamburg, Germany, 2011. Cerebrovasc Dis 2012; 
34: 290-6.
19. National Kidney Foundation. K/DOQI clinical practice 
guidelines for chronic kidney disease: evaluation, clas-
sification and stratification. Am J Kidney Dis 2002; 39 
(2 Suppl 1): S1-266.
20. Catena C, Verheyen N, Pilz S, et al. Plasma aldosterone 
and left ventricular diastolic function in treatment-naïve 
patients with hypertension: tissue-Doppler imaging 
study. Hypertension 2015; 65: 1231-7.
21. Edelmann F, Tomaschitz A, Wachter R, et al. Serum aldo-
sterone and its relationship to left ventricular structure 
and geometry in patients with preserved left ventricular 
ejection fraction. Eur Heart J 2012; 33: 203-12.
22. Lee MY, Lai WT. Plasma renin level and aldosterone 
to renin ratio are associated with presence of carotid 
plaques in patients with stable coronary artery dis-
ease. J Renin Angiotensin Aldosterone Syst 2015; 16: 
1159-67.
23. Wang JG, Staessen JA, Li Y, et al. Carotid intima-media 
thickness and antihypertensive treatment: a meta-anal-
ysis of randomized controlled trials. Stroke 2006; 37: 
1933-40.
24. Devereux RB, Dahlof B, Gerdts E, et al. Regression of 
hypertensive left ventricular hypertrophy by losartan 
compared with atenolol. The Losartan Intervention for 
Endpoint Reduction in Hypertension (LIFE) trial. Circula-
tion 2004; 110: 1456-62.
25. Kisaka T, Ozono R, Ishida T, Higashi Y, Oshima T, Kiha- 
ra Y. Association of elevated plasma aldosterone-to-re-
nin ratio with future cardiovascular events in patients 
with essential hypertension. J Hypertens 2012; 30: 
2322-30.
26. Newton-Cheh C, Guo CY, Gona P, et al. Clinical and ge-
netic correlates of aldosterone-to-renin ratio and rela-
tions to blood pressure in a community sample. Hyper-
tension 2007; 49: 846-56.
27. Tomaschitz A, Maerz W, Pilz S, et al. Aldosterone/renin 
ratio determines peripheral and central blood pressure 
values over a broad range. J Am Coll Cardiol 2010; 55: 
2171-80.
28. Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial 
stiffness, and the response to aldosterone antagonism 
in essential hypertension. Am J Hypertens 2005; 18: 50-5.
29. Rajzer M, Klocek M, Kawecka-Jaszcz K. Effect of amlodip-
ine, quinapril, and losartan on pulse wave velocity and 
plasma collagen markers in patients with mild-to-mod-
erate arterial hypertension. Am J Hypertens 2003; 16: 
439-44. 
30. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation 
between renal dysfunction and cardiovascular out-
comes after myocardial infarction. N Engl J Med 2004; 
351: 1285-95.
31. Terata S, Kikuya M, Satoh M, et al. Plasma renin activity 
and the aldosterone-to-renin ratio are associated with 
the development of chronic kidney disease: the Ohasa-
ma Study. J Hypertens 2012; 30: 1632-8.
32. Aronow WS. Update of treatment of heart failure with 
reduction of left ventricular ejection fraction. Arch Med 
Sci Atheroscler Dis 2016; 1: e106-16.
33. Sacks CA, Jarcho JA, Curfman GD. Paradigm shifts in 
heart-failure therapy – a timeline. N Engl J Med 2014: 
371: 989-91.
34. Evans M, Carrero JJ, Szummer K, et al. Angiotensin-con-
verting enzyme inhibitors and angiotensin receptor 
blockers in myocardial infarction patients with renal 
dysfunction. J Am Coll Cardiol 2016; 67: 1687-97.
35. van Vark LC, Bertrand M, Akkerhuis KM, et al. Angioten-
sin-converting enzyme inhibitors reduce mortality in hy-
pertension: a meta-analysis of randomized clinical trials 
of renin-angiotensin-aldosterone system inhibitors in-
volving 158 998 patients. Eur Heart J 2012; 33: 2088-97.
36. Elijovich F, Weinberger MH, Anderson CA, et al. Salt sen-
sitivity of blood pressure: a  scientific statement from 
the American Heart Association. Hypertension 2016; 
68: e7-46.
37. Mente A, O’Donnell M, Rangarajan S, et al. Associations 
of urinary sodium excretion with cardiovascular events 
in individuals with and without hypertension: a pooled 
analysis of data from four studies. Lancet 2016; 388: 
465-75.
